Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

TxCell Raises EUR 12.4 Million (USD 16 million) in a Third Financing Round

Published: Tuesday, November 27, 2012
Last Updated: Tuesday, November 27, 2012
Bookmark and Share
InnoBio fund supports TxCell development.

TxCell SA has announced that it raised EUR 12.4 million in a third financing round. This additional capital was provided by the InnoBio fund, managed by CDC Entreprises, for EUR six million and by TxCell’s existing shareholders Auriga Partners and Seventure Partners.

These additional financial resources will enable TxCell to pursue the development of its lead product candidate, Ovasave®.

Ovasave is an antigen-specific Treg cell-based immunotherapy for the treatment of Crohn’s disease in patients who are refractory to current treatments.

“The technology platform developed by TxCell offers a promising new therapeutic alternative for the many patients with severe chronic inflammatory diseases and who are refractory to current treatments,” said Laurent Arthaud, deputy CEO at CDC Entreprises.

Arthaud continued, “We are impressed by the innovative therapeutic approach and the encouraging positive clinical data obtained so far by TxCell. The company has a strong and experienced management team in place and capital injection will provide the necessary resources to confirm the clinical findings obtained so far and reach the next important development milestone.”

To date, TxCell has completed a first in man PhI/II clinical study carried out in France to evaluate the tolerability and efficacy of Ovasave.

The results showed good tolerance and a positive efficacy signal. This was particularly impressive in the best dose group with 75 per cent of patients treated responding.

The study results have just been published in Gastroenterology, the most prominent journal in the field of gastrointestinal diseases and featured in Nature Reviews Gastroenterology and Hepatology.

These promising results meant that TxCell decided to pursue the clinical development of Ovasave in the same patient population by performing a larger international blinded and placebo controlled phase IIb study.

“TxCell is now armed to move forward and to execute its business plan,” said Francois Meyer, chairman and chief executive officer at TxCell. “We value highly the support of InnoBio, as it acknowledges and validates our pioneering cell-based therapeutic approach for treating diseases with high unmet medical need. We also highly appreciate the continued support from our existing investors. This further investment gives us the necessary financial flexibility to progress as a leader in the emerging field of cell-based immunotherapies.”

TxCell has been funded by venture capital since 2004. A total of EUR 23.9 million has been invested in A/B rounds by five major investors, Auriga Partners, AXA Private Equity, CDC Entreprises via BioAm Fund, Innovation Capital and Seventure.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

TxCell Appoints MaSTherCell for the Manufacturing of Ovasave®
First clinical batches could be manufactured as soon as Q2 2016.
Saturday, August 01, 2015
TxCell Announces FDA Acceptance of IND for Ovasave
IND grants TxCell option of extending current phase 2b study from EU to US.
Tuesday, June 30, 2015
TxCell Announces a Temporary Partial Hold of Activities at its Pilot Manufacturing Unit
Company expects only potential limited impact on clinical product timeline.
Wednesday, June 24, 2015
TxCell: Financial Information for the First Quarter of 2015
Company reports its revenues for 1Q 2015.
Thursday, May 14, 2015
TxCell Appoints Stéphane Boissel as Chief Executive Officer
Company promotes Miguel Forte to Chief Operating Officer.
Saturday, May 02, 2015
TxCell and Trizell Amend Collaboration Agreement
Company appoints the Cell Therapy Catapult to perform process and manufacturing development.
Friday, May 01, 2015
Strengthening of Cash Position and Development of ASTrIA Product Platform
Positive results for Col-Treg, second product candidate, in an auto-immune uveitis model.
Tuesday, April 07, 2015
TxCell to Present at Upcoming US and French Investment Conferences
Conferences include Alliance for Regenerative Medicine's 3rd Annual Regen Med Investor Day, New York, March 25 and the Portzamparc PEA-PME Forum, Paris, April 1.
Saturday, March 28, 2015
Key TxCell Patent to be Granted in the US for its Lead Product Ovasave®
Patent ensures protection for Ovasave® in the US until 2030 minimum.
Thursday, March 19, 2015
TxCell to Present at ROTH Capital Partners Investor Conference in US
TxCell invited to speak at largest US meeting for investors in emerging growth companies.
Friday, February 27, 2015
TxCell Reports Revenues for 2014 and Updates on Upcoming Milestones
Ovasave and Col-Treg regulatory status update in the United States, expected mid-2015.
Thursday, February 05, 2015
TxCell Receives EUR 1 Million Milestone Payment
Milestone payment triggered by first patient enrolment in the phase IIb clinical trial for refractory Crohn’s disease.
Thursday, January 29, 2015
TxCell to Present at the Cell & Gene Therapy Forum 2015
Company to present its experience with Cell Therapy at the Cell & Gene Therapy Forum 2015, Washington.
Saturday, January 24, 2015
TxCell Receives EU Orphan Drug Designation for Col-Treg
A proof of principle clinical study is planned to start in the first half of 2015, with top line results of this study expected mid-2016.
Friday, December 19, 2014
TxCell Announces Start of Phase IIb Clinical Trial with Ovasave®
Top line results of this study are expected end 2016/early 2017.
Tuesday, December 09, 2014
Scientific News
Study Finds Brain Chemicals that Keep Wakefulness in Check
Researchers to develop new drugs that promote better sleep, or control hyperactivity in people with mania.
Sorting Through Cellular Statistics
Aaron Dinner, professor in chemistry, and his graduate student Herman Gudjonson are trying to read the manual of life, DNA, as part of the Dinner group’s research into bioinformatics—the application of statistics to biological research.
Playing 'Tag' with Pollution lets Scientists See Who's It
Using a climate model that can tag sources of soot from different global regions and can track where it lands on the Tibetan Plateau, researchers have determined which areas around the plateau contribute the most soot — and where.
Women’s Immune System Genes Operate Differently from Men’s
A new technology reveals that immune system genes switch on and off differently in women and men, and the source of that variation is not primarily in the DNA.
Long Telomeres Associated with Increased Lung Cancer Risk
Genetic predisposition for long telomeres predicts increased lung adenocarcinoma risk.
First Artificial Ribosome Designed
Researchers at the University of Illinois at Chicago and Northwestern University have engineered a tethered ribosome that works nearly as well as the authentic cellular component, or organelle, that produces all the proteins and enzymes within the cell.
High-Resolution 3D Images Reveal the Muscle Mitochondrial Power Grid
NIH mouse study overturns scientific ideas on energy distribution in muscle.
Expanding the Brain
A team of researchers has identified more than 40 new “imprinted” genes, in which either the maternal or paternal copy of a gene is expressed while the other is silenced.
Identifying a Key Growth Factor in Cell Proliferation
Researchers discover that aspartate is a limiter of cell proliferation.
Study Uncovers Target for Preventing Huntington’s Disease
Scientists from Cardiff University believe that a treatment to prevent or delay the symptoms of Huntington’s disease could now be much closer, following a major breakthrough.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!